Combining three mechanisms in frontline kidney cancer failed in both LightSpark-012 and COSMIC trials. Adding more drugs increases toxicity, forcing dose holds and reductions that prevent adequate delivery across biologically relevant targets without precise patient selection.
Multi-drug triplets often fail due to compounded toxicities that prevent complete dosing. Bispecific antibodies that hit two targets, such as VEGF and PD-1, may bypass delivery hurdles and create a tolerable backbone for future combination regimens.
When refractory kidney cancer regimens lack overall survival advantages, clinicians cannot justify universal doublet escalation over monotherapy. Treating physicians must weigh the non-survival benefits of higher response rates against subjecting patients to the increased toxicities of multi-drug regimens.
Unlike prostate cancer, kidney cancer management currently lacks validated high- and low-volume criteria to guide treatment intensity. Clinicians recognize variations in disease pace, metastatic sites, and synchronous versus metachronous timing, but still treat patients uniformly in trials.
Volga demonstrated overall survival benefits using only three neoadjuvant cycles of enfortumab vedotin combined with durvalumab. This finding questions whether patients truly need the extensive nine cycles delivered in Keynote-905, igniting debates over balancing oncologic cure against toxicity and healthcare costs.
In clinical practice and clinical trial arms planned for nine perioperative cycles of EV-pembrolizumab, most patients fail to complete therapy due to adverse events. Consequently, real-world clinicians already administer de-escalated regimens resembling shorter three-cycle protocols out of necessity.
Pharmaceutical sponsors typically lack commercial incentives to fund non-inferiority trials testing shorter durations or treatment cessation. Academic groups must step forward to lead discontinuation studies, such as stopping immunotherapy after stable disease, which offer significant quality-of-life benefits.
Trial evidence across STAMPEDE and ENZARAD suggests systemic treatment intensification primarily aids localized prostate cancer patients with very high-risk disease, such as conventional N1 status. Broad high-risk classifications remain too heterogeneous to justify intensified AR pathway inhibition for everyone.
